Ozempic and Wegovy have received a lot of publicity as revolutionizing treatment options for obesity. Both medications form a class of GLP-1 receptor agonists, which mimic a hormone in the body called glucagon-like peptide-1 and are involved in the regulation of appetite and blood sugar. Indeed, in initial clinical studies, the majority of those on the drugs lost 15% to 22% of body weight, hence much optimism. For most patients, these medications are underwhelming for about 20% of patients due to minimal weight loss or other challenges.

Take a closer look at why the weight loss drugs may not work for everyone, together with what options exist when they don't deliver the expected outcomes.

Why Weight Loss Drugs May Not Work

While GLP-1 receptor agonists have produced phenomenal responses in a majority of patients, it remains a reality that these drugs work differently for different people. Here's why:

1. Genetic and Hormonal Variability

Weight loss medications interact with complex systems in the body that differ from person to person. Genetics, hormones, and individual brain responses to energy regulation play significant roles in determining how a person responds to drugs like Ozempic and Wegovy.

2. Underlying Medical Conditions

Other conditions, such as sleep apnea, may be prevalent and prevent or delay the achievement of weight loss goals. Prescription drugs like antidepressants, steroids, or contraceptives are other medications that can nullify weight loss medication benefits.

3. Unrealistic Expectations

Often, they come to these medications with enormous hopes; expecting the promised rapid and dramatic weight loss. Progress creates disappointment if it has not stalled. In patients who rigidly follow recommended lifestyle modifications, frustration and disappointment are most common.

Why it is Important to Identify Non-responders

For most patients, the effectiveness of GLP-1 receptor agonists is evident within a few weeks of treatment. Weight loss typically begins within a few weeks of initiating therapy and tends to increase with dosage. However, some patients respond very little, if at all, despite strict adherence to their regimen.

For nonresponders, this can feel like a dead end. However, understanding the unique complexities of obesity is essential. This condition stems from brain dysfunction, and the pathways that contribute to weight regulation differ among individuals.

Alternative Treatment Options

When Ozempic or Wegovy doesn’t yield desired results, there are still many paths to explore:

1. Switching to Another GLP-1 Drug

For example, some patients who don't respond well to one GLP-1 receptor agonist might find success with another drug in the same class. Newer medications, such as Zepbound, target other hormone pathways and seem promising even for those not responsive to earlier drugs.

2. Use of Older Medications

While there is much to say about newer drugs, older treatments can still be useful and work for some patients. One can also seek the help of a medical provider specializing in obesity treatments in order to identify the best alternatives.

3. Lifestyle Changes

Diet, exercise, sleep, and stress management continue to be integral components of any weight loss program. New changes may be small but can make an enormous difference in one's health and success.

4. Medical Management of Obesity

It is a complex disorder, and most patients should receive a multidisciplinary treatment. Collaboration with an obesity-aware doctor may mean access to tailored treatment plans, ranging from psychological support all the way to metabolic testing, and many others.

Why Side Effects of Weight Loss Drug Ozempic May Be a Barrier

For others, side effects like nausea, vomiting, or diarrhea hinder them from continuing with these drugs. These symptoms often reduce as the body becomes accustomed, but for some, they might be severe enough to stop treatment altogether. In those instances, alternative drugs or procedures become vital to find.

Long-term effects of Ozempic or Wegovy on the Brain

Another largely unexplored area relates to GLP-1 drugs' long-term effects on the brain's regulation of hunger and satiety. Although GLP-1 drugs suppress appetite and can lead to effective weight loss, emerging research suggests that they may also affect brain reward mechanisms, changing the way patients experience foods.

This aspect could prove of paramount significance in the future treatment of obesity. Perhaps GLP-1 receptor agonists do indeed affect and rewire the brain's reward pathways and will thus provide sustained benefits beyond discontinuation. However, more research is required to understand this phenomenon fully.

While for many, Ozempic and Wegovy have revolutionized obesity treatment, these are certainly not a one size fits all. Nonresponders need not lose hope- alternative strategies and medications abound. A consultation with an obesity expert healthcare provider is essential to put together a comprehensive, tailored treatment plan.

The route toward effective weight loss may be challenging, but with the evolution of obesity medicine and a better understanding of individual needs, there is a path forward for everyone.

While doctors across the world recommend ensuring that fluoride and other protective minerals make up your toothpaste, your body produces its very own amino acid that protect your entire dental cavity.

Arginine, an amino acid that is already present in saliva, can turn bacteria from damaging to protective in your mouth, a study has found.

When sugars from food are broken down by the many bacteria living in the mouth, acids are produced that gradually damage tooth enamel and lead to cavities. This is known as dental caries. Over time, this acid dissolves tooth enamel and causes cavities.

However, researchers at Aarhus University in Denmark have discovered that regular arginine treatment can significantly reduced the overall acidity levels in the mouth and prevent tooth decay.

Yumi Del Rey, microbiologist at Aarhus, said: ""Our results revealed differences in acidity of the biofilms, with the ones treated with arginine being significantly more protected against acidification caused by sugar metabolism."

How Did The Study Take Place?

Volunteers were then asked to instructed to dip the dentures in a sugar solution for 5 minutes, immediately followed by distilled water (as placebo) or arginine for 30 minutes, one on each side. This was to be repeated three times a day, with arginine treatment done on the same side each time.

Sebastian Schlafer, professor at the Department of Dentistry and Oral Health, explained: "The aim was to investigate the impact of arginine treatment on the acidity, type of bacteria, and the carbohydrate matrix of biofilms from patients with active caries."

After 4 days of this process, the biofilms were developed and the dentures were removed for detailed analysis. The researchers compared dental plaques grown on customized dentures on both sides of each participant's mouth using a special pH-sensitive dye called C-SNARF-4.

How Does Arginine Work?

Additionally, the team also began to look into how arginine might be reducing acidity, by taking stock of which bacteria and sugars were present in each sample.

Biofilms treated with arginine showed lower levels of a sugar called fucose, while another sugar, galactose, was concentrated towards the outer surface of the biofilm, meaning both sugars were away from the tooth enamel.

After analyzing the DNA of bacteria present, the researchers found that arginine treatment significantly reduced a specific population of Streptococcus bacteria known to produce acid, while slightly increasing other bacterial strains that can metabolize arginine.

The scientists noted that while more research is needed into the arginine's effectiveness, the amino acid could be a promising new addition to oral hygiene products such as toothpaste or mouthwash.

For decades, a cancer diagnosis often came with fear and uncertainty. Today, that narrative is slowly changing. New national data shows that more people diagnosed with cancer in the United States are living longer than ever before, reflecting steady progress in prevention, early detection, and treatment.

For the first time, the five-year survival rate across all cancers has reached 70 percent. That means seven out of ten people diagnosed with cancer now live at least five years after diagnosis, a significant improvement from the mid-1970s, when survival hovered around 50 percent. This shift marks one of the most encouraging milestones in modern cancer care.

Why Survival Rates Are Rising

Several factors are driving this improvement. Reduced tobacco use has played a major role, particularly in lowering deaths from lung and other smoking-related cancers. At the same time, better screening tools are catching cancers earlier, when treatment is more likely to work. Advances in therapies, including targeted drugs, immunotherapy, and improved chemotherapy regimens, have also transformed outcomes for many patients.

What stands out is that survival gains are not limited to less aggressive cancers. Even cancers once considered highly fatal, such as lung cancer, liver cancer, and certain blood cancers, are seeing meaningful improvements. In some advanced-stage cancers where survival was previously measured in months, people are now living years longer than expected.

Living Longer, Even With Advanced Cancer

One of the most striking trends is improved survival among people with metastatic cancer, where the disease has spread to other parts of the body. While these cancers remain difficult to treat, progress is undeniable. Survival rates for metastatic lung cancer, for example, have increased severalfold since the 1990s. Similar gains have been seen in metastatic colorectal cancers.

These improvements suggest that cancer is increasingly being managed as a long-term condition rather than an immediate terminal illness for many patients. Continued research has played a critical role in making this possible.

The Role of Research and Funding

The steady rise in survival has not happened by chance. It reflects decades of scientific investment, clinical trials, and innovation. However, experts warn that recent cuts to health research funding could slow future progress. Breakthroughs in cancer care rely heavily on sustained support for research, and disruptions to that pipeline could affect outcomes years down the line.

While the current numbers are encouraging, they also serve as a reminder that progress must be protected and expanded.

Persistent Gaps and Disparities

Despite overall gains, cancer outcomes are not improving equally for everyone. The report highlights ongoing racial and ethnic disparities in both cancer incidence and survival. Certain populations continue to experience higher death rates and lower survival, often due to limited access to early screening, timely diagnosis, and high-quality treatment.

Lung cancer is expected to remain the leading cause of cancer-related deaths in the coming years. While smoking remains the biggest risk factor, an increasing number of people who have never smoked are also being diagnosed, raising new questions about environmental and genetic risks. Some experts argue that screening guidelines need to evolve to reflect these changes.

A Growing Community of Survivors

As survival improves, the number of people living with a history of cancer is rapidly growing. There are already over 18 million cancer survivors in the US, and that number is expected to cross 22 million within the next decade. This brings new challenges.

Survivors often face long-term physical, emotional, and financial effects, and the healthcare system is still catching up when it comes to consistent survivorship care. Many primary care providers are not trained to monitor cancer recurrence or manage late treatment effects, leaving gaps in follow-up care.

Covid is returning, as the National Health Service, NHS UK warned that there has been a "bounce back" in respiratory viruses this winter, along with COVID too on the rise. While UK was already struggling with flu and norovirus on the rise, cases of COVID have also risen. The latest data from the UK Health and Security Agency (UKHSA) show that the number of patients in hospital beds with COVID per day has risen from 0.87 per 100,000, as compared with 0.77 per 100,000 the previous week.

NHS national medical director Professor Meghana Pandit said: “It’s clear that the worst is far from over for the NHS this winter, with hospitals again experiencing a rise in patients admitted with flu and other respiratory virus cases last week.”

What New COVID Variants Are We Dealing With In 2026?

Since the pandemic, there have been many variants of COVID. The virus has continued to evolve. Two new variants that caused the spike in cases in autumn were XFG, known as Stratus, and NB.1.1, known as Nimbus.

Stratus: It is a subvariant of Omicron variant and made of previous variants LF.7 and LP.8.1.2. It was first detected in a sample on January 27, 2025. Whereas, Nimbus was first detected on January 22, 2025. It also originated from the same omicron variant, which was the reason for spike in 2023.

The World Health Organization (WHO) describes stratus as a "variant under monitoring" after several countries in South East Asia reported a rise in new cases and hospitalizations with this variant being detected.

COVID Symptoms 2026: Fatigue Emerges As The Most Common Symptom

Among studies that focused on how symptoms appear together, fatigue stood out as the most consistently reported issue. It often occurred alone or alongside problems such as muscle and joint pain, brain fog, or breathlessness. Other symptom pairings that appeared frequently included loss of smell and taste, anxiety with depression, and various forms of musculoskeletal pain.

When researchers classified patients based on affected organ systems, respiratory problems were the most widespread, seen in about 47% of long COVID patients. Neurological symptoms followed at 31%, while gastrointestinal issues were reported by 28%. The authors stressed that these percentages reflect how often these clusters appeared within long COVID cases studied, not how common they are in the general population.

A smaller number of studies sorted patients by how severe their symptoms were, dividing them into mild, moderate, or severe categories using symptom scores, symptom counts, or quality-of-life measures. Three studies used clinical indicators for classification, including abnormal triglyceride levels and signs of restricted lung function on imaging.

As per the Centers for Disease Control and Prevention (CDC), here are the common COVID symptoms:

• Fever or chills
• Cough
• Shortness of breath or difficulty breathing
• Sore throat
• Congestion or runny nose
• New loss of taste or smell
• Fatigue
• Muscle or body aches
• Headache
• Nausea or vomiting
• Diarrhea

How To Know If You Have COVID?

CDC says, look out for these signs:

• Trouble breathing
• Persistent pain or pressure in the chest
• New confusion
• Inability to wake or stay awake
• Lips and nail beds may appear pale, grey or blue